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PERSPECTIVE
Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Alice Di Rocco, Federico De Angelis, Michela Ansuinelli, Robin Foà and Maurizio Martelli
Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Rome, Italy
ABSTRACT
Introduction: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell
lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder. Novel additional
predictors of outcomes and new therapeutic strategies are being introduced to improve outcomes.
Areas covered: This review aims to analyse the recent molecular discoveries in DLBCL, the rationale of
novel molecular driven treatments and their impact on DLBCL prognosis, especially in ABC-DLBCL and
High Grade B Cell Lymphoma. Pre-clinical and clinical evidences are reviewed to critically evaluate the
novel DLBCL management strategies.
Expert commentary: New insights in DLBCL molecular characteristics should guide the therapeutic
approach; the results of the current studies which are investigating safety and efficacy of novel ‘X-
RCHOP’ will probably lead, in future, to a cell of origin (COO) based upfront therapy. Moreover, it is
necessary to identify early patients with DLBCL who carried MYC, BCL2 and/or BCL6 rearrangements
double hit lymphomas (DHL) because they should not receive standard R-CHOP but high intensity
treatment as reported in many retrospective studies. New prospective trials are needed to investigate
the more appropriate treatment of DHL.
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1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most frequent
type of adult non-Hodgkin lymphoma (NHL) in Western coun-
tries, comprising 25–30% of all cases of NHL [1]. In the United
States, about 24,000 new cases/years are estimated to have
been diagnosed in 2015 [2].
Benefits in the outcome of patients with DLBCL have been
achieved following the introduction of the anti-CD20 mono-
clonal antibody rituximab in the therapeutic algorithms. The
first positive experiences with rituximab in association with
the standard CHOP regimen (adriamycin, cyclophosphamide,
vincristine, prednisone) were observed in elderly patients (60–
80 years) and then further confirmed in young patients
(<60 years) by the MInT trial that led FDA to approve the
use of rituximab as first-line treatment for DLBCL in 2006 [3,4].
Despite these improvements, approximately 40% of DLBCL
patients will relapse or have a refractory disease. The use of
potentially more intensive chemotherapies has failed to
demonstrate a higher efficacy compared to R-CHOP. Several
randomized studies using autologous stem cell transplanta-
tion (ASCT) in first remission or dose-dense strategies have
failed to document a clear advantage over R-CHOP [5,6].
For these reasons, clinical and translational researchers
have tried to identify clinical and/or biologic hallmarks with
the aim of better stratifying patients at high risk of relapse/
refractoriness with standard therapy. The International
Prognostic Index (IPI) score currently in use is easy to perform
but does not take into consideration the novel biologic acqui-
sitions generated in the last years [7].
The common feeling that DLBCL is a complex neoplastic
disease is clearly underlined by the differences in clinical pre-
sentation, morphology, genetic, and molecular profiles. The
only recognition of morphologic variants (e.g. immunoblastic
DLBCL) has failed to define a valid correlation with clinical
outcome, probably because influenced by the observers’
experience and interpretation. However, among the
RICOVER-60 trial, the German High-Grade Lymphoma Study
Group (DSHNHL) tested the prognostic impact of immunoblas-
tic morphology in 949 patients. In this analysis, the authors
showed that the immunoblastic morphology was an adverse
prognostic factor in multivariate analysis [8], furthermore,
another study revealed that the immunoblastic variant of
DLBCL has a high frequency of underlying MYC transloca-
tion [9].
The translational studies of DLBCL have allowed to identify
different patterns of gene expression profile (GEP) which cor-
relate with clinical outcome. In 2000, Alizadeth et al. [10],
using DNA microarrays, showed that there are different GEPs
among the tumors of DLBCL patients. They identified two
molecularly distinct subtypes of DLBCL based on the cell of
origin (COO). One subtype expressed genes characteristic of
germinal center B-cells (germinal center B-cell like DLBCL or
GCB-DLBCL); the second subtype expressed genes normally
induced during in vitro activation of peripheral blood B cells
(activated B-cell like DLBCL or ABC-DLBCL). This means that
DLBCL can arise from different cell types in the microenviron-
ment of the lymph node. Approximately 15–20% do not fit
into these two categories and are molecularly unclassifiable
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[11]. Different immunohistochemistry (IHC) methods are also
used to classify DLBCL according to COO, using these algo-
rithms, DLBCL is classified as GCB or non-GCB [12–14].
The GCB-DLBCL is associated with a favorable outcome
when treated with standard RCHOP therapy; however, the
better understanding of the molecular pathogenesis of the
two subgroups has led to investigation of new targeted ther-
apeutic strategies to improve the worse outcome of the
patients with ABC/non-GCB DLBCL.
The importance of recognizing the two biologic categories
has been highlighted in the most recent World Health
Organization (WHO) revision of lymphoma classification [15],
which considers acceptable to use the IHC algorithm since
GEP is not routinely utilized. It must, however, be underlined
that IHC is not able to classify the 15% of patients identified by
GEP as unclassifiable.
Newer methods based on quantification of RNA transcripts
extracted from formalin-fixed paraffin-embedded tissues have
concordant results with conventional microarray GEP and may
overcome this difficulty in COO classification [16].
In addition to the COO, recent genetic and proteomics
studies identified a prognostic role for MYC and BCL2 genetic
translocations and/or protein co-expression. Earlier studies
reported that 5–10% of DLBCL harbored MYC, BCL2, and/or
BCL6 translocations, and were named as ‘double hit’ lym-
phoma (DHL), or triple hit lymphoma (THL). The new revised
WHO lymphoma classification recognized this category as the
new entity “high-grade B-cell lymphoma (HGBL) with rearran-
gements of MYC, BCL2 and/or BCL6ʹ’[15].
A comprehensive understanding of the mutations which
drive DLBCL pathogenesis is not still clear; whole-exome
sequencing could have a role in the identification of signifi-
cant gene mutations. Lohr et al. demonstrated in a small series
of patients (DLBCL) that the mutations of three genes – KRAS,
BRAF, and NOTCH1 – have a role in the oncogenesis of DLBCL.
If those data will be confirmed in a larger number of patients,
it could be possible to expand our knowledge regarding
DLBCL over the simple COO [17].
The aim of this review is to analyze the recent molecular
discoveries in DLBCL biology and the subsequent potential
new treatment options.
1.1. Beyond IPI: new prognostic factors in DLBCL
The prognostic factors in DLBCL can be divided into those
related to the patient (e.g. age and performance status), those
related to the tumor (e.g. stage, tumor burden, proliferating
fraction, extranodal involvement), those related to aggressive-
ness indicators (e.g. serum lactate dehydrogenase (LDH) and
beta-2-microglobulin levels). However, considering the
advanced knowledge on the molecular bases of deregulated
signaling in DLBCL, new factors related to the complex biology
of the disease need to be added (Figure 1).
IPI is routinely used to predict the outcome of patients with
DLBCL and remains a robust prognostic tool [7]. IPI was ori-
ginally created in the pre-rituximab era and it was based on a
combined score of five clinical parameters: age > 60, elevated
serum LDH, ECOG performance status ≥ 2, Ann Arbor stage III
or IV, number of involved extranodal sites ≥ 2, which reflect
the extent of the tumor involvement and the host status.
Based on this score, four risk categories (low, low-intermedi-
ate, high-intermediate, and high) have been identified with 5-
year overall survival (OS) of 73%, 51%, 43%, and 26%, respec-
tively. To stratify patients 60 years or younger, the age
adjusted IPI, which includes stage, LDH, and performance
status, is more commonly used in the clinical practice than
IPI [18]. Sehn et al. [19] confirmed the prognostic value of the
Figure 1. Clinical and biological factors affecting response in DLBCL.
LDH - lactate dehydrogenase.
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IPI score in a cohort of R-CHOP-treated patients, but they were
able to distinguish only two risk group instead of the four
ones of the original IPI. They subsequently proposed a revised
version (R-IPI) that considered three risk groups with 4-year OS
rates of 94%, 79%, and 55%, respectively. The German group
analyzing the data from three prospective phase II/III trials
demonstrated that the conventional IPI has still a prognostic
relevance in the R-CHOP era [20].
With the aim to improve the risk stratification by IPI in
Rituximab era, a new IPI was built using raw clinical data from
the National Comprehensive Cancer Network (NCCN) database:
the NCCN-IPI. This new score system better discriminated low-
and high-risk subgroups (5-year OS: 96% vs. 33%) than the IPI
(5-year OS: 90% vs. 54%), respectively [21].
To date, we are in the molecular era of disease definition and
even though the IPI score remains a robust prognostic index, it
does not address the underlying biologic heterogeneity of
DLBCL. Additional predictors are necessary to refine the prog-
nostic stratification and identify more precisely high-risk patients.
DLBCL is characterized by highly heterogeneous genetic
and cytogenetic aberrations. Some alterations are frequently
found in DLBCL, probably playing an important role in lym-
phomagenesis or progression of the disease. These include
rearrangements and mutation involving BCL2, c-MYC, BCL6,
and TP53, and many of these biological parameters have
been identified as prognostic factors in DLBCL [22] (Table 1).
1.1.1. Cell of origin
As described above, the molecular evaluation of the COO has
identified two major subtypes with a different outcome: the
GCB-DLBCL and the ABC-DLBCL. Notably, this remarkable bio-
logic difference was also associated with a different prognostic
likelihood: GCB-DLBCL presented a significantly better out-
come when treated with R-CHOP, with a 5-year OS of 76%
compared to 34% in ABC-DLBCL (p < 0.01) as reported in the
Hans et al. study. In the same study, in multivariate analysis, a
high IPI score (3–5) and the non-GCB phenotype were inde-
pendent adverse predictors (p < .0001) [12]. Hans et al. sug-
gested an IHC algorithm which evaluates the expression of
three cellular proteins: CD10, BCL6, and MUM1/IRF4 in identi-
fying GCB or non-GCB type; however, this algorithm shows
only a 79% of concordance with GEP [12]. The introduction of
other IHC markers like GCET1 and FOXP1 enhanced the sensi-
tivity of IHC in the definition of the COO; a higher grade of
concordance between IHC and GEP (93%) was found by Choi
et al., which considered GCET1, CD10, BCL6, MUM1, and
FOXP1 markers [13]; a similar grade of concordance (92.6%)
between GEP and IHC was also demonstrated by Visco et al.
by using CD10, GCET1, FOXP1, BCL6, and MUM1 evaluation
algorithm [14]. However, there were discrepancies in the clin-
ical outcomes predicted by these different algorithms and, to
date, none of them was robust to identify the DLBCL COO
compared to the gold standard GEP classifier [23–25]. Lenz
et al. profiled gene expression signatures in pretreatment
biopsy of 181 patients with DLBCL treated with CHOP and
233 patients treated with R-CHOP. They demonstrated that
even in the RCHOP cohort, the patients with GC-DLBCL had
higher OS rates than those with ABC-DLBCL, 74% vs. 40% [26].
These data suggest that the identification of the molecular
profile of DLBCL can further refine the traditional prognostic
score derived from the clinical assessment of patients; how-
ever, the difficulties of using GEP analysis has limited the use
of this method in the daily clinical practice.
Recently, RNA-based new technologies have enabled to
quantify the level of expression of the most significant genes
of the GCB/ABC signature, in formalin-fixed paraffin-
embedded tissues (FFPET). One of the two major platforms
developed, named NanoString (Lymph2Cx), has a rapid turn-
around time of 36 h and recent reports indicate that this
assay may allow to identify more robustly the COO than the
widely used algorithm of Hans et al [16]. When applied to a
large cohort of DLBCL treated with RCHOP, the Lymph2Cx
signature was able to classify GCB versus ABC DLBCL, and the
prognosis of ABC type was poorer as expected [27]. No study
has formally compared different gene set Nanostring signa-
tures to date. The feasibility and accuracy of the Nanostring
technology is being assessed among a prospective trial
(ROBUST trial). This technology seems the most advanced
to date in terms of validation against GEP gold standard
and reproducibility between laboratories.
In addition, in many medical centers high-throughput
sequencing technologies (next-generation sequencing [NGS])
are becoming currently available and are be able either to
identify specific target mutations either to assess mRNA
expression levels from FFPE samples at limited costs. In the
near future, we could have the combination of gene expres-
sion level and targeted sequencing of mutations (such as
MYD88, GNA13) as benchmark.
Beyond GEPs, genomic gains and losses of specific onco-
genes or tumor suppressors, as MYC and CDKN1B gains or
TP53 and CDKN2A losses, were significantly associated with
outcome independently of the ABC and GCB subtypes [28].
1.1.2. CD5
CD5 is an antigen typically expressed on the surface of normal
and neoplastic T cells, as well as on a subset of normal IgM-
secreting B cells (B1 repertoire) and of neoplastic B cells [29].
De novo CD5+ DLBCLs represent a distinct subgroup of
DLBCL first described in 1995, that occurs in approximately
5–10% of newly diagnosed cases and that shows an aggres-
sive clinical course and poor prognosis [30,31]. Common char-
acteristics of patients with CD5+ DLBCL are older age, a high/
high-intermediate IPI at diagnosis, frequent extra-nodal invol-
vement, and an ABC phenotype. Most patients show a primary
refractory disease or relapses after front-line chemotherapy. So
far, there is no consensus on the optimal first-line treatment
for CD5+ DLBCL [32]. In one of the largest series of de novo
CD5+ DLBCLs diagnosed and treated in Western countries,
Alinari et al. [33] retrospectively reviewed the clinical features
and outcome of 102 patients with de novo CD5+ DLBCL
treated with rituximab plus chemotherapy. The 3-year pro-
gression-free survival (PFS) for the ABC and GCB subtypes
was 34% and 45%, respectively, while the 3-year OS for ABC
and GCB-subtypes was 62% and 67%, respectively. These data
suggest that CD5+ DLBCL patients have a poor outcome
despite the COO.
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1.1.3. Epstein–Barr virus (EBV)
Epstein–Barr virus (EBV)-positive lymphoproliferative disorders
are more common in patients with congenital or acquired
immunodeficiency disorders. Oyama et al. [34] were the first
to describe EBV-positive DLBCL (E-DLBCL) in immunocompe-
tent patients. These types of lymphomas are frequently diag-
nosed in elderly patients and are characterized by an
aggressive clinical course, poor response to chemotherapy,
high rate of relapse after first-line treatment, and decreased
OS, even in the rituximab era [35,36]. Age-related senescence
of the immune system seems to be one of the most important
factors in the pathogenesis of E-DLBCL causing an impaired
cytotoxic T-cell immune surveillance toward EBV [37]. The
2008 WHO classification of lymphoid neoplasm classified this
disease in a provisional entity as EBV-positive DLBCL of the
elderly, defined as a clonal EBV+ B-cell proliferation occurring
in immunocompetent patients with more than 50 years.
Despite the name, recent reports have shown that this
entity can also affect younger patient;, however, in the Hong
et al. study, the EBV positivity did not affect the OS in the
young patients (<50 years) but remained a predictor of inferior
survival in the patients with more than 50 years [36]. Recently,
in another study, Lu et al. investigated the outcome of EBV-
positive patients in different age cohorts using different EBER
cut-offs. Using both the 20% and 50% EBER cut-off values,
they found that EBV-positive patients showed a significantly
worse OS and PFS than the negative cases, irrespective of
age [38].
1.1.4. TP53
TP53 is a cellular protein encoded by homologous genes
localized in the short arm of chromosome 17. It has a crucial
role in the regulation of cell cycle, DNA repair, apoptosis, and
senescence with an important tumor suppression activity [39].
Several studies have shown that different types of TP53 muta-
tions are an independent prognostic factor of poor outcome
in newly diagnosed DLBCL treated with CHOP chemotherapy
with or without rituximab [40–42].
Young et al [43] in 2008 found a strong association
between TP53 mutations (MUT-TP53) and clinical features
such as younger age at diagnosis, high serum LDH levels,
bulky mass, and a high IPI risk group. They also found that
TP53 mutations prognostically stratify only the GCB-DLBCL
group into distinct risk subsets. In the series by Xu-Monette
et al. [42], a large cohort of newly diagnosed DLBCL (506
patients) treated with R-CHOP was evaluated for TP53 gene
mutations by exon sequencing. The 5-year OS was 65.9% for
patients with wild type TP53 (WT-TP53) compared to 47.8% for
those with MUT-TP53 DLBCL. The 5 year PFS was 63.5% for WT-
TP53 patients versus 46.3% for MUT-TP53 cases. In contrast
with previous studies, in this series TP53 mutations seem to
impact on survival in both GCB and ABC subtypes of DLBCL,
with a major impact on GCB DLBCL. They also evaluated TP53
overexpression by IHC as a surrogate of TP53 mutation and it
proved to be a good predictor of mutation when a cut-off
greater than 50% is used.
Interestingly, Gebauer et al. [44] in a recent retrospective
study found an elevated frequency of TP53 mutations in newly
diagnosed DHL with MYC and BCL2 aberrations, but not in
MYC-BCL6 DHL. The prognostic effect of this association was
not evaluated.
1.1.5. BCL6
BCL6 is a zinc finger transcriptional factor encoded by a proto-
oncogene localized on chromosome 3. This protein acts as a
transcription repressor of many genes with a major role in GC
formation and in the regulation of lymphocyte differentiation
and survival [45]. A deregulated expression, due to transloca-
tions or mutations, has been implicated in the lymphomagen-
esis process [46].
It has been demonstrated that the BCL6 gene is one of
the most frequently translocated or mutated genes in
DLBCL. In fact, its rearrangement occurs up to 30–35% of
newly diagnosed cases leading to a deregulation of the
expression and function of the BCL6 protein [47,48]. The
effect of BCL6 translocation or hypermutation on prognosis
remains uncertain; different results have been reported,
some associated with a favorable prognosis [49,50], others
with an unfavorable outcome [47,51] and others with no
impact at all [52].
In the pre-rituximab era, BCL6 protein expression had been
identified as one of the strongest predictors of outcome in
DLBCL [53]. In fact, patients with a high expression of BCL6
were the ones showing the longer OS, but this favorable
prognostic role of BCL6 expression was not confirmed when
rituximab was added to CHOP [51].
GCB-DLBCL shows in general a high expression of BCL6 by
IHC and is associated with a better OS than the ABC subgroup
which does not show a BCL6 overexpression.
In the series by Iqbal et al. [50], the authors demonstrated
that the translocation occurs mostly in the ABC subtype, while
gene mutations occur mostly in the GCB subtypes. In their
cohort of patients, BCL6 overexpression, evaluated by IHC at a
30% cut-off, was significantly associated with a favorable OS
despite the COO. Also, higher levels of BCL6 mRNA were
associated with a better outcome in the whole cohort.
In contrast, Akyurek et al. [49] reported on 239 patients
with DLBCL evaluated for BCL6, BCL2, and MYC rearrange-
ments. They found that a BCL6 rearrangement had a sig-
nificantly negative impact on survival in patients with the
non-GCB phenotype, while there was no impact in patients
with GCB-DLBCL. Also, BCL6 did not affect PFS. In contrast
with previous studies, they did not find a correlation
between BCL6 rearrangement and BCL6 expression in IHC
[46,52].
The extreme heterogeneity of these results could be
explained by the absence in most studies of simultaneous
MYC rearrangements assessment. More data on BCL6 rearran-
gements, as single genetic alteration, are needed to conclu-
sively define the impact on OS and PFS for a better risk
stratification of patients at diagnosis.
1.1.6. BCL2
The BCL2 protein is a mitochondrial outer-membrane protein
encoded by the BCL2 proto-oncogene localized on chromo-
some 18. It plays a critical role in promoting cell survival and
inhibition of proapoptotic proteins such as BAX and BAK [53].
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Its expression is frequently found abnormal in human cancers
such as lymphomas and leukemia. High expression levels of
BCL2 in neoplastic cells have been associated with resistance
to chemotherapy agents [54].
BCL2 is frequently found overexpressed in both the ABC
and GCB DLBCL subtypes. Up to 35% of GCB DLBCL shows a
BCL2 rearrangement with a t(14;18) (q32;q21), which is asso-
ciated with high BCL2 mRNA levels and high expression of the
BCL2 protein [54,55]. In a few cases, BCL2 is translocated to an
Ig light chain (IGκ, IGλ) locus, as in t(2;18)(p11;q21.3) or t
(18;22)(q21.3;q11). BCL2 translocation is rarely found in
DLBCL with an activated phenotype, suggesting that the over-
expression of BCL2 found in this subset has an alternative
pathogenesis [56]. The constitutive activation of the NF-kB
pathways [57] is the pathogenetic hallmark of ABC DLBCL
which leads to an increased transcription of the BCL2 gene;
the other mechanism that may explain the overexpression is
the amplification of the locus 18q21 [58] on which BCL2
resides and that is found in particular in ABC DLBCL [59].
Recent studies conducted in cohorts of patients treated
with R-CHOP have evaluated the prognostic significance of
BCL2 expression. The results still remain conflicting, possibly
due to the different cut-off levels used for the IHC analysis and
due to the heterogeneity of the DLBCL cohorts with variable
proportions of GCB and ABC DLBCL. In some series, BCL2
expression did not predict for either PFS or OS since the
addition of rituximab to CHOP chemotherapy seemed to elim-
inate the gap between BCL2-positive and BCL2-negative
patients [60,61] reported in the pre-rituximab era [62,63].
Iqbal et al. [64] evaluated BCL2 expression (with a 50% cut-
off for IHC analyses) in 221 patients treated with R-CHOP
demonstrating that BCL2 protein expression was significantly
associated with a poorer OS (p = 0.009) and event-free survival
(EFS; p = 0.001). When patients were divided according to COO
by GEP analysis, BCL2 expression had an impact on outcome
only in GCB patients. In fact, patients with a GCB phenotype
and BCL2 expression had a significantly lower OS (p = 0.03)
and EFS (p = 0.002) than those with BCL2-negative GCB DLBCL.
Visco et al. [65] in 2013 found that, as expected, amplifica-
tion of BCL2 was more frequently associated to an ABC phe-
notype (70%, p < 0.0001), while t(14;18) was more associated
to a GCB phenotype (84%, p < 0.0001). They found no impact
on survival of BCL2 rearrangements on the whole DLBCL
cohort, but when patients were stratified according to the
COO (evaluated by GEP), patients with GCB-DLBCL and iso-
lated BCL2 translocations had a significantly worse outcome
than patients without BCL2 rearrangements (p = 0.0002) irre-
spective of any MYC rearrangement. Their outcome was similar
to that of patients with ABC-DLBCL (p = 0.30). They also
evaluated the prognostic significance of BCL2 overexpression
and confirmed the association with an inferior outcome in
GCB patients.
1.1.7. MYC
MYC (c-MYC) is a proto-oncogene sited in the long-arm of
chromosome 8 that encodes for a multifunctional transcrip-
tion factor that plays a critical role in cell cycle progression,
differentiation, metabolism immune response, and apoptosis
[66]. Mutations, rearrangements, and translocations of this
gene have been associated with a variety of hematopoietic
tumors such as Burkitt lymphoma, DLBCL, and acute lympho-
blastic leukemia. Overexpression of the MYC protein can be
detected in a large proportion (about 30–50%) of DLBCL and it
is highly expressed (>70% of cells) in the nuclei of DLBCL with
MYC rearrangements or amplification [67]; not all MYC trans-
locations result in MYC protein expression [68]. Only one-third
of DLBCL cases with substantial (>30–40% cells) MYC protein
expression carry MYC gene alterations [67,69,70].
MYC deregulated expression in lymphoma most commonly
results from a chromosomal translocation. However, other
mechanisms such as amplification, mutation, or microRNA-
dependent mechanisms can lead to increased MYC protein
expression [71]. The t(8;14)(q24;q23) translocation or, more
rarely, t(2;8)(p12;q24) and t(8;22)(q24;q11) that juxtapose the
c-MYC gene to the immunoglobulin heavy chain (IgH)/light
chains (Igκ/λ) gene promoter, cause a high level of transcrip-
tion of the MYC gene. It can be detected in almost 5–10% of
DLBCL [69,72]. In 20–30% of MYC-translocated DLBCL, it is also
possible to find the coexisting BCL2 and/or BCL6 rearrange-
ments determining the DHL or THL [22].
The prognostic significance of MYC overexpression in
newly diagnosed DLBCL has been evaluated by IHC analysis
only in a few studies. The optimal cut-off point for MYC
expression is controversial, ranging from 40% to 70% in
most studies. Valera et al. [70] in their cohort of 196 patients
treated mostly with R-CHOP found that MYC overexpression
frequently correlated with older age, advanced stage disease,
high serum LDH concentration, and high-risk IPI score, and
that it was associated with an unfavorable impact on both PFS
and OS (p = 0.007) even with a cut-off threshold of 10%.
In a recent paper, Xu-Monette et al. [73] determined the
presence of MYC expression by IHC (n = 535) and MYC rear-
rangement status by FISH analysis (n = 344) in a well-charac-
terized DLBCL cohort. They found that the MYC expression
level was significantly higher in ABC-DLBCL than in GCB-
DLBCL. In particular, using a 70% threshold for positivity,
37.8% of ABC and 27.9% of GCB-DLBCL showed a high expres-
sion of MYC, while a translocation/rearrangement occurred
more frequently in GCB-DLBCL (16.3% vs. 7.3%, respectively).
GCB-DLBCL patients with a concomitant MYC overexpression
and translocation had a significantly worse OS compared to
GCB-DLBCL patients with low MYC expression. In ABC-DLBCL,
only patients with overexpression but without gene rearran-
gements had a significantly worse OS, especially if associated
with a BCL2 overexpression. Interestingly, MYC rearranged
DLBCL without MYC protein overexpression did not show a
significantly worse survival.
Tzankov et al. [74] evaluatedMYC rearrangements by FISH in a
cohort of patients treated with R-CHOP and confirmed that
within the MYC rearranged cases (39/376) a higher frequency
was found in GCB-DLBCL (27/39; 69%). All types of MYC rearran-
gements (except for amplification which had no impact) were
associated with a poor disease-specific survival. Regarding the
prognostic role of the MYC protein expression, the expression of
the MYC protein in up to 75% or in up to 95% (the most relevant
predictive score of MYC rearrangements) of tumor cells was
associated with an adverse OS; no significant survival difference
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has been observed when other cut-off scores have been used
(50% or 40%) between MYC protein positive and negative cases.
It is clear that the evaluation of MYC expression and rear-
rangement is important in all newly diagnosed DLBCL.
However, since FISH analysis is not routinely applicable in all
DLBCL new cases, a two-step approach either with a protein
expression assessment either with a FISH examination in those
cases with a high protein expression, seems today a practical
and less expensive sequential approach (Figure 2).
1.1.8. Double expressor, DHL, and THL
Alterations of the MYC gene are frequently associated with a
BCL2 rearrangement and/or overexpression (20–35% of cases)
[72], while the association with alterations of the BCL6 gene is
less common. The presence of a rearrangement of both the
MYC and BCL2 genes defines the new entities named ‘double
hit lymphoma (DHL)’ or ‘triple hit lymphoma (THL)’ if there is
also a BCL6 rearrangement. The 2016 WHO classification of
lymphoid neoplasms includes all DLBCL with MYC and BCL2
and/or BCL6 rearrangements in a single category designated
as HGBL, with MYC and BCL2 or BCL6 translocations. DHL and
THL are characterized by a particularly aggressive behavior
and by a dismal prognosis. Cases with an aberrant expression
of MYC and BCL2, without chromosomal alterations, have
been defined as ‘double expressor lymphoma (DEL)’ or ‘triple
expressor lymphoma (TEL)’ if the aberrant expression of BCL6
is also documented [15]. Most HGBL with rearrangements are
of GC origin and conversely almost all DEL are of ABC origin.
Johnson et al. [68] studied the frequency of an abnormal
MYC and BCL2 expression (29% and 44%, respectively) in a
cohort of patients with DLBCL; a concomitant pathological
expression of both of them was found in 21% of cases, while
a chromosomal translocation of the MYC gene was recorded
in 11% of patients. A worse outcome was observed in patients
who expressed concomitantly high levels of MYC and BCL2
proteins, and in cases with both genes translocated. When
they were treated with the classic R-CHOP schedule, the 5-
year OS of the three groups – DEL, DHL, and classic DLBCL –
was 36%, 27%, and 71%, respectively (Figure 3). The clinical
adverse outcome when both genes are altered pointed to a
facilitating role of both of them in the acquisition of a parti-
cularly aggressive behavior. It was also clear that patients
carrying chromosomal translocations presented a worse out-
come compared to patients with only an abnormal expression
of BCL2 and MYC.
Green et al. [75] analyzed 193 paraffin-embedded samples
of patients with de novo DLBCL treated with RCHOP using HIC
for MYC, BCL2, CD10, BCL6, and MUM1/interferon regulatory
factor 4, and FISH for MYC and BCL2. They identified 6% of
DHL of patients in FISH analysis who presented as expected a
very poor OS (p = .002). Furthermore, depending on MYC and
BCL2 expression, a double-hit score (DHS) was assigned to all
patients with DLBCL. High expression of both MYC and BCL2
protein (DHS2) was significantly associated with lower CR rate
(p = .004), shorter OS (p = .001), and shorter PFS (p = .001).
The clinical impact of the BCL6 rearrangement in DHL is
more difficult to define because of the low incidence of this
combined alteration. Aukema et al. [76] reported that MYC/
BCL6 DHL maintains a similar clinical outcome as that of
patients with MYC/BCL2 DHL, with an increasing trend in
older age compared to MYC/BCL2 DHL. In contrast with the
previous study, a more recent analysis of Ye et al. [77] showed
that only DHLs with MYC and BCL2 rearrangement had a
significant inferior outcome while the concurrent MYC/BCL6
rearrangements did not correlate with poorer OS and PFS,
similar results were obtained by Copie-Bergman and collea-
gues [78].
It is still uncertain how to treat these pathologic entities
within DLBCL because of the few prospective data. Oki et al.
[79] reported that R-EPOCH (rituximab, etoposide, prednisone,
vincristine, cyclophosphamide, doxorubicin) versus R-CHOP
was associated with a longer EFS. In the largest study of
Figure 2. Algorithm for the identification of double hit lymphoma (DHL) and
double expressor lymphomas (DEL) if FISH is not applicable for every new
diagnosis of DLBCL. The first step evaluates the protein expression of MYC,
Bcl2 and Bcl6 by IHC, based on the results only selected cases will be evaluated
by FISH analysis.
DLBCL - diffuse large B cell lymphoma; IHC – immunohistochemistry.
Figure 3. Overall survival of patients with diffuse large B cell lymphoma (DLBCL)
according MYC and BCL2 translocation (double hit lymphoma) or MYC and BCL2
protein expression (double expressor, DE). [From Johnson NA et al. J Clin Oncol
2012; 30(28):3452–3459, modified].
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patients with DHL, Petrich et al. [80] found that more intensive
induction treatment such as DA-EPOCH-R, R-HyperCVAD, or
R-CODOX-M/IVAC were associated with a better PFS when
compared with the standard R-CHOP (p = 0.001). The OS was
significantly better in the intensive induction treatment group
only after adjusting for adverse risk factors. They also did not
find a significant improvement in PFS with consolidative ASCT
in first CR. In a recent systematic review and meta-analysis of
394 DHL patients treated with R-CHOP or different alternative
strategies as DA-EPOCH-R or high intensity chemotherapy (like
R-HyperCVAD or R-CODOX-M/R-IVAC), it was shown that DA-
EPOCH-R as upfront therapy can reduce the risk of progression
compared to R-CHOP and to other treatments, but the OS was
not significantly different among the different schemes [81].
For these reasons, DA-EPOCH-R is under investigation in a
prospective study for DHL.
1.2. Toward molecular-driven treatment strategies
Currently, a subtype-specific treatment for patients with
DLBCL could become a reality in view of the improved mole-
cular technologies and of the development of new targeted
drugs.
IHC and GEP techniques that permit a real-time evaluation
of the COO on FFPET tissues are now available; the possibility
of recognizing rapidly the molecular COO subtype is thus
easier and potentially feasible in the clinical practice.
Furthermore, the improved knowledge of the signaling path-
ways, genetic mutations, and biomarkers operational in lym-
phomagenesis has led to the expansion of new, biologically
based therapies with a differential activity in specific DLBCL
subtypes, particularly ABC-DLBCL.
The rationale of the greater activity of new drugs in ABC-
DLBCL resides in the mechanism of lymphomagenesis of this
subtype that owes its name from the post-GCBs arrested along
the plasmacytic differentiation pathway. ABC-DLBCL has a
gene expression signature that is largely similar to that of
peripheral blood B cells, including the expression of genes
that define the end stage memory B cells or plasma cells,
such as the transcription factors interferon response factor 4
(IRF4) and X-box binding protein 1 (XBP1) [82]. The constitu-
tive expression of IRF4, which is normally expressed during
lymphocyte activation, has been shown to be an important
part of the proliferative stimulation, as well as the XBP1 gene
[83]; recently, mutations of the MYD88 gene (which is known
to be mutated in Waldestrom’s macroglobulinemia) have been
reported to have a role in the activation of the IRF4 pathway
[84]. The most important hallmark of ABC-DLBCL is the
upregulation of BCR signaling by the NF-kB proliferative path-
way [84–86]. The important role of the alteration of the NF-kB
family is underlined by the evidence that it is able to induce
resistance to apoptosis [87]. The in vitro inhibition of the NF-kB
pathway using inhibitors of NF-kB has proven to be particu-
larly cytotoxic in ABC-DLBCL but not in GCB-DLBCL [85]. In
addition to the NF-kB pathway, other mutations play a role in
ABC-DLBCL pathogenesis, like the activation of the specific
B-cell surface antigens CD79A and CD79B [82].
On the other hand, an important hallmark of the GCB-DLBCL
subtype is the absence or low expression of the NF-κB pathway: it
has been demonstrated that GCB-DLBCL survival is not influenced
by stimulation through NF-κB [82]. This observation has important
clinical implications because drugs which downmodulate the
activity of the NF-κB pathway are likely not to have a role in this
setting. Interestingly, activating mutations of the histone methyl-
transferase EZH2 gene (enhancer of zeste homolog 2) have been
demonstrated to play an important role in the process of GCB-
DLBCL differentiation [88].
Considering the above, a number of clinical trials have
investigated novel therapeutic agents targeting the BCR path-
way or its downstream constituents in all DLBCLs. These com-
prise mainly immunomodulatory drugs (IMiDs), proteasome
inhibitors and BCR signaling pathway inhibitors (Table 1).
1.2.1. Lenalidomide
Lenalidomide, as other IMiDs, has antineoplastic effects that
include direct antineoplastic activity, immunologic effects
mediated by inhibition of tumor cell proliferation, angio-
genesis, and stimulation of cytotoxicity mediated by
immune cells of the tumor microenvironment, including B,
T, NK, and dendritic cells [89]. Phase II studies have demon-
strated the efficacy of lenalidomide as single agent in
relapsed/refractory NHL; in particular, improved response
rates and PFS have been observed in ABC-DLBCL [90]. The
activity of lenalidomide has been confirmed also in
relapsed/refractory DLBCL as single agent or in combination
with rituximab. Despite the small sample size (only 23
patients), Zinzani et al. [91] published data that indicate
the potential efficacy of lenalidomide and rituximab fol-
lowed by lenalidomide maintenance in relapsed/refractory
elderly DLBCL patients with a CR rate of 26%, a median
duration of CR of 5 years (range 30–78 months) and a DFS
of 75% at 6 years. The greatest efficacy of lenalidomide in
ABC-DLBCL depends on direct targeting of IRF4, leading to
the downregulation of the NF-kB pathway activity and
enhancement of the interferon pathway [92]. Recently, the
results of two phase II trials of lenalidomide combined with
Table 1. Novel drugs with a focus on their biological targets and their activities on GC and ABC DLBCL.
Drug Target DLBCL ABC DLBCL GC
Lenalidomide Microenvironment +++ –
Bortezomib NF-KB +++ –
Venetoclax Pro-apoptotic Bcl-2 family + ++
Ibrutinib BTK +++ +
Alisertib AURORA kinase ++ –
BAY1238090,
0610, OTX015, and JQ1
BET bromodomain Preclinical data Preclinical data
NF-KB: nuclear factor kappa-light-chain-enhancer of activated B cells; BTK: Bruton’s tyrosine kinase; GCB: germinal center B cell; ABC: activated B cell; DLBCL: diffuse
large B cell lymphoma.
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R-CHOP in untreated DLBCL have been reported. The first
study by the Italian group (REAL07 trial) demonstrated an
overall response rate (ORR) of 92% (CR 86%, PR 6%) and 2-
year PFS and OS of 80% (95% CI 64–89) and 92% (95% CI
79–97), respectively [93]. In the second study, the Mayo
Clinic also reported an ORR of 98% (59/60 patients) with
80% of CR (48/60), and EFS and OS rates at 2 years of 59%
(95% CI 48–74) and 78% (95% CI 68–90), respectively.
Significantly, the study showed no difference in 2-year PFS
or OS for lenalidomide plus R-CHOP in the ABC and GCB
subtypes (60% vs. 59%, p = 0.89 and 83% vs. 75%, p = 0.61);
the addition of lenalidomide to the standard treatment of
DLBCL (R-CHOP) could overcome the negative prognostic
effect of the ABC phenotype [94] (Figure 4). Based on these
data, a randomized, double blind, phase III trial (ROBUST;
NCT02285062) comparing lenalidomide plus R-CHOP versus
placebo in untreated ABC-DLBCL according to GEP analysis
on FFPET is now ongoing and actively recruiting. The pri-
mary endpoint of this study is PFS [95] (Figure 5).
1.2.2. Bortezomib
Proteasome inhibitors, such as bortezomib, have a key role in the
suppression of the NFkB pathway that is constitutively activated in
ABC-DLBCL, as discussed. Bortezomib was one of the first drugs
investigated that demonstrated favorable results in increasing the
activity of chemotherapy in relapsed/refractory DLBCL based on
themolecular subtype, as showedbyDunleavy et al. inmulticenter
trial [96]. However, only 49 patients were enrolled in this trial from
3 centers and it would be ideal designing a randomized trial of DA-
EPOCH plus or minus bortezomib with stratification by GCB and
ABCDLBCL subtypes to getmore significant results. Ruan et al. [97]
in a phase II single arm study evaluated the combination of
bortezomib with R-CHOP in 40 previously untreated DLBCL and
mantle cell lymphoma, and showed that unlike in DLBCL treated
Italian FIL Study
Mayo Clinic Study
Figure 4. 2-years PFS in GCB-DLBCL and non-GCB DLBCL for patients treated R2-CHOP in the Italian.
FIL (Federazione Italiana Linfomi) and Mayo clinic studies; PFS - progression-free survival; GCB-DLBCL - germinal center-diffuse large B cell lymphoma; R2 - rituximab + lenalidomide; CHOP -
cyclophosphamide, doxorubicin, vincristine, prednisone.
Figure 5. Robust trial: study design. In this trial, the determination of the cell of origin was performed with Nanostring technique.
DLBCL - diffuse large B cell lymphoma; GCB - germinal center B cell; R - rituximab; CHOP - cyclophosphamide, doxorubicin, vincristine, prednisone.
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with chemoimmunotherapy alone, patientswithABC-DLBCL had a
similar outcome of GCB-DLBCL. Considering this result, the combi-
nation of Bortezomib R-CHOP has been evaluated in two phase II
randomized trials: LYM-2034 trial and PYRAMID trial. In the first
trial, bortezomib plus R-CAP or/and plus R-CHOPwas compared to
R-CHOP alone in patients with ABC-DLBCL, failing to show an
improved efficacy of bortezomib plus immunochemotherapy in
terms of ORR and PFS.
In the PYRAMID trial, there were also no significant differ-
ences between bortezomib combined with R-CHOP and
R-CHOP in 2-year PFS (82% vs. 78%, p = 0.76) or OS (93% vs.
88%, p = 0.76) [98,99]. Meanwhile, a randomized, double-blind,
phase III study (REMoDL-B trial) has completed accrual. The
aims of this study were to compare R-CHOP plus bortezomib
to R-CHOP alone in DLBCL as front-line therapy determining
the genetic subtype by central GEP assay. Based on the pre-
liminary analysis, no difference in terms of ORR and CR was
observed between the ABC and GCB molecular subtypes. The
final results on 2-year PFS, primary endpoint of the study, are
still pending following a 30-month follow-up analysis [100].
Overall, these results seem to prove that bortezomib did not
enhance the outcome in ABC–DLBCL; however, we can wait
for the final results of the REMoDL-B trial regarding the 2-year
PFS to confirm this hypothesis.
1.2.3. Ibrutinib
Another important mechanism in the constitutive activation of
the NFkB pathway through the BCR is modulated by the
Bruton tyrosine kinase (BTK) and several specific BTK inhibitors
have been developed. Ibrutinib is a BTK inhibitor that cova-
lently blocks this TK and is orally bioavailable. Recently, in a
phase I/II multicenter study that involved 80 patients with
relapsed or refractory DLBCL, ibrutinib as single agent pro-
duced complete or partial responses in 37% (14/38) of patients
with ABC-DLBCL, but only in 5% (1/20) of GCB-DLBCL patients
(p = 0.0106). One of the interesting components of this study
was the mutational status analysis of the tumors. ABC tumors
with CD79a/CD79b (BCR subunits) and MYD88 mutations
showed a high response rate, a result that is in line with the
cross communication in vitro between BCR and MYD88 path-
ways. However, the highest number of responses was
observed in ABC-DLBCL patients lacking BCR mutations (9/
29; 31%), suggesting that the oncogenic BCR signaling might
be initiated by nongenetic mechanisms [101].
In a phase Ib study of ibrutinib plus R-CHOP for treatment-
naïve DLBCL patients, Younes et al. [102] demonstrated that
the combination with ibrutinib was well tolerated and that 18
patients who received the recommended phase 2 dose wit-
nessed an overall response. On the basis of these data, a
randomized, double-blind, phase III trial (PHOENIX,
NCT01855750) comparing R-CHOP versus R-CHOP plus ibruti-
nib in untreated ABC-DLBCL has completed recruitment. The
primary endpoint of the study is the EFS at 7 years, and the
preliminary results are pending (Figure 6).
1.2.4. New agents
Most agents active in ABC-DLBCL have little efficacy in the
GCB subtype. Patients with GCB-DLBCL have a better clinical
outcome than those with ABC-DLBCL, but a relapse after
induction therapy is associated with a poor outcome regard-
less of the COO. Moreover, DHL have a GCB phenotype in the
majority of cases. Mostly in DHLs and GCB-DLBCLs new agents
may be used according to two strategies: (1) to modulate the
transcription of MYC, BCL2, or BCL6; (2) to target the MYC,
Figure 6. Phoenix trial: study design. In this trial, the determination of the cell of origin was performed with Immunohistochemistry alghoritm.
GCB- germinal center B cell; IHC- immunohistochemistry; R-IPI- revised international prognostic index
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BCL2, or BCL6 proteins. For the first strategy, BET bromodo-
main inhibitors are currently in preclinical development
(BAY12380907, CPI-0610, OTX015, and JQ1) [103] and the
first reports look promising. JQ1 is a small-molecule inhibitor
of BET bromodomain that has shown in vitro activity by inhi-
biting the binding of the BRD4 co-activator (BET family) to
chromatin and suppressing MYC-driven transcription. Studies
in preclinical mouse models have demonstrated that JQ1
causes cell death, and cell-cycle arrest in DLBCL cells of both
GCB and ABC subtypes [104]. Preliminary results of a phase I
study with OTX015, another BET bromodomain inhibitor, have
demonstrated a good activity and a good safety profile.
OTX015 in vitro is able to target the NF-κB/TLR/JAK/STAT
signaling pathways, genes modulated by MYCC and E2F1,
and its activity in vitro results synergistic with mTOR and BTK
inhibitors [105].
The BCL2 family and the MYC protein also represent a
target for new agents as navitoclax and venetoclax (BCL2-
inhibitors), and a MYC-targeting aurora A kinase inhibitor
(alisertib). Navitoclax (ABT263) showed antilymphoma activity
in a phase I trial, but this was associated with a high hemato-
logic toxicity with thrombocytopenia due to BCL-xL inhibition
[106]. Venetoclax (ABT-199) is another BCL2 inhibitor engi-
neered to remove the BCL-xL inhibition and thus to reduce
the risk of thrombocytopenia. Venetoclax has shown activity in
DHL and THL cell lines. However, in a phase I study in patients
with relapsed/refractory NHL, the ORR was highest in
Waldestrom’s macroglobulinemia (4/4) and in mantle cell lym-
phoma (21/28, 75%); the activity of venetoclax in DLBCL was
present but modest (6/34, 18%), with only four patients
obtaining a CR (12%) [107].
Alisertib, an aurora kinase inhibitor, has been combined
with rituximab and vincristine in a mouse model with DLBCL
coexpressing MYC and BCL2, and a high efficacy in inducing
cell death and a potential cure has been reported [108].
2. Expert commentary
The era of treating all patients with DLBCL only with the
conventional R-CHOP regimen is getting to an end and the
current challenge in DLBCL therapy is to move new promising
agents to the front-line treatment (X + R-CHOP) in order to
improve the results of R-CHOP. As a first step to improve
outcome in DLBCL, it is necessary to identify at diagnosis
patients with poor prognostic features. Since GEP is expensive
and not readily available to all laboratories, and the IHC algo-
rithms lead to a low reproducibility between different labora-
tories, the 2008 WHO classification considered as provisional
the subclassification of DLBCL-NOS. Since then we have been
witnessing a better understanding of the genetic mechanisms
underlying the disease. The prognostic value of the COO has
been conclusively confirmed, with the ABC subtype having a
significantly inferior 3-year PFS (40% vs. 75%; p = < .001) in
patients treated with R-CHOP. In addition, we have unraveled
the very different oncogenic pathways that are important
prognostically and could have relevant therapeutic implica-
tions. In the revised 2016 WHO classification, it is required
that the two genetic subtypes of DLBCL – GCB/ABC – are
identified at diagnosis. The IHC is accepted instead of GEP
and the Hans algorithm is still the most utilized even though
new methods as Lymph2Cx using paraffin-embedded tissue
will be accessible to most laboratories. In fact, the 20-gene
assay using the Nanostring technology gives concordant
results with GEP, is reproducible between laboratories, and
may become a robust alternative to the current IHC-based
algorithm.
Additionally, it is necessary to recognize cases of DLBCL
with MYC and BCL2 and/or BCL6 rearrangements, DHLs or
THLs now designated as HGBL by the revised 2016 WHO
classification, distinguishing those from cases without rearran-
gements with high MYC and BCL2 expression, DE lymphomas.
This is a highly critical point because DHL should not be
treated with R-CHOP but they should receive intermediate or
high intensity schemes of chemotherapy as reported in many
retrospective studies.
Because of the lack of prospective data, we need new
prospective trials to better investigate how to treat DHL.
Contrary, the COO is under investigation in several first-line
randomized phase II and III trials evaluating the efficacy of
R-CHOP combined with the new agents with the aim of
improving the PFS of those cases of DLBCL-NOS with poor
outcome identified as ABC-DLBCL.
The CC-5013-DLC002 (ROBUST trial) is an ongoing rando-
mized study which is investigating the addition of lenalido-
mide to R-CHOP in untreated ABC type DLBCL, using the
Nanostring technology. The other ongoing trials are the
Phoenix trial that has evaluated the combination of ibrutinib
with R-CHOP in ABC-DLBCL and the REMoDL-B study that has
investigated the addition of bortezomib to R-CHOP. These
studies have completed their accrual and we are waiting for
the preliminary results. These studies could also give us infor-
mation about the treatment of DEL because most patients
express an ABC phenotype reflecting a constitutive NF-kB
activation.
3. Five-year view
In the next few years, a greater availability of a network of
sophisticated laboratory methodologies aimed at a better
understanding of the biology of DLBCL in the real life day-
to-day clinical practice will be required. The Nanostring tech-
nology may become a promising alternative to IHC analysis;
the test is not expensive, may prove reproducible and capable
of creating an added value at defining the COO in only a few
days. Knowing the COO at the onset of the disease will be
important to decide the specific treatment if the results of the
current studies will confirm that X-RCHOP is better than
R-CHOP in a given subgroup of patients, leading to a perso-
nalized upfront therapy truly guided by the molecular char-
acteristics of the disease.
Key issues
● The evaluation of the cell of origin identifies two major sub-
types of DLBCL, germinal center B-cell like (GCB) and acti-
vated B-cell (ABC) lymphoma which are associated with a
different prognostic likelihood. The IHC test remains a valid
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routine clinical test to identify the COO instead of GEP, until
new methodologies – as Nanostring – will be validated.
● To date, the IPI score remains a robust prognostic index,
but it does not address the underlying biologic heteroge-
neity of DLBCL.
● The understanding of the key signalling and regulatory
pathways of DLBCL have identified new biologic prognostic
factors and new targeted agents have been developed.
● DHL and THL are new pathologic entities defined as HGBL
with rearrangements of MYC and BCL2 and/or BCL6 with an
aggressive presentation and a very poor outcome following
R-CHOP therapy. Intensified strategies, for example Burkitt’s
like schemes, should be considered for these subtypes.
● DEL cases do not have genetic alterations of MYC and BCL2
but present a double protein overexpression which is asso-
ciated with a lower CR rate and shorter OS than DLBCL, but
have a better outcome than DHL. New combined strategies
with biologic agents could improve their outcome.
● New agents that inhibit the NFkB pathway seem to be more
effective in ABC-DLBCL because of the constitutive activa-
tion of the NFkB-pathway in this subtype.
● The results of the current trials testing the combination of
R-CHOP with novel agents (lenalidomide, bortezomib, ibru-
tinib) – X + R-CHOP – could help to overcome the adverse
prognosis of ABC-DLBCL
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